Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	62.02	23.61	27.46	10.16	28.65	13.29
Revenue Growth (YoY)	161.81%	-14.02%	170.26%	-64.53%	115.61%	3.50%
Cost of Revenue	17.39	7.42	2.17	0.22	2.06	1.31
Gross Profit	44.63	16.2	25.29	9.94	26.59	11.98
Selling, General & Admin	72.71	54.92	35.09	15.61	9.23	8.44
Research & Development	25.94	42.04	39.03	19.23	9.64	8.32
Operating Expenses	105.04	103.2	74.89	34.84	18.86	16.76
Operating Income	-60.41	-87	-49.6	-24.9	7.73	-4.78
Interest Expense	-8.48	-7.35	-1.5	-0.34	-0.38	-7.09
Interest & Investment Income	3.9	2.18	4.54	1.51	0.26	0.09
Other Non Operating Income (Expenses)	-3.22	2.06	-0.1	15.16	-0.03	-0.18
EBT Excluding Unusual Items	-68.22	-90.12	-46.66	-8.57	7.59	-11.97
Merger & Restructuring Charges	-	-	-	-	-	-0.83
Gain (Loss) on Sale of Investments	148.33	-0.02	0.61	-0.58	-0.01	-
Other Unusual Items	-	-	-	-	-16.1	-
Pretax Income	21.4	-90.14	-46.05	-26.81	-8.52	-12.79
Income Tax Expense	18.75	15.37	-	-0.03	0.03	-0.03
Net Income	2.64	-105.51	-46.05	-26.77	-8.56	-12.76
Preferred Dividends & Other Adjustments	6.55	-	-	-	54.34	-
Net Income to Common	-3.91	-105.51	-46.05	-26.77	-62.9	-12.76
Shares Outstanding (Basic)	53	46	35	34	30	4
Shares Outstanding (Diluted)	53	46	35	34	30	4
Shares Change (YoY)	33.78%	30.46%	2.79%	15.87%	647.72%	114.79%
EPS (Basic)	-0.07	-2.28	-1.30	-0.78	-2.11	-3.21
EPS (Diluted)	-0.08	-2.28	-1.30	-0.78	-2.11	-3.21
Free Cash Flow	-46.53	-69.67	-33.83	-18.81	10.34	-1.97
Free Cash Flow Per Share	-0.89	-1.51	-0.95	-0.55	0.35	-0.49
Gross Margin	71.96%	68.59%	92.09%	97.81%	92.81%	90.18%
Operating Margin	-97.41%	-368.47%	-180.63%	-245.07%	26.98%	-35.98%
Profit Margin	-6.30%	-446.85%	-167.69%	-263.48%	-219.54%	-96.03%
Free Cash Flow Margin	-75.02%	-295.04%	-123.20%	-185.12%	36.08%	-14.84%
EBITDA	-53.85	-80.61	-48.6	-23.96	7.99	-4.51
EBITDA Margin	-86.82%	-	-176.97%	-235.78%	27.87%	-33.92%
D&A For EBITDA	6.57	6.39	1.01	0.94	0.26	0.27
EBIT	-60.41	-87	-49.6	-24.9	7.73	-4.78
EBIT Margin	-97.41%	-	-180.63%	-245.07%	26.98%	-35.98%

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q